$VRTX News

Vertex Pharmaceuticals (VRTX) Posts Positive Phase 3 Results For Povetacicept

What Vertex Pharmaceuticals Holders Bought Into

Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 - Slideshow

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026

Vertex Pharmaceuticals Announces Phase 3 RAINIER Results Supporting Potential Of Povetacicept In IgA Nephropathy Published In The New England Journal Of Medicine; Vertex’s Povetacicept Shows 49.8% Greater Proteinuria Reduction vs. Placebo In Phase 3 IgAN Trial; FDA Decision Expected November 30

Vertex Pharmaceuticals Receives FDA's Orphan Designation For Atumelnant To Treat Endogenous Cushing’s Syndrome

Vertex Pharmaceuticals’ New Drugs Are Gaining Ground. Is That Enough for Investors?

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

Vertex Appoints Daniel Brennan to its Board of Directors

What Vertex Pharmaceuticals (VRTX)'s Pancreas Recovery Data Means For Shareholders

Vertex (VRTX) Stock May Be 35% Undervalued Despite New ALYFTREK Data

Vertex Pharmaceuticals (VRTX) Pancreatic Function Data Puts Its Undervalued Narrative In Focus

Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?

Sickle cell gene therapies offer new hope, but access remains a major challenge

Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts

Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders

What You Need to Know Ahead of Vertex Pharmaceuticals’ Earnings Release

Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know